Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Cheng, Heather H ^a,b   Yi, Hye Son ^b   Kim, Yeonju ^c   Kroh, Evan M ^a   Chien, Jason W ^a   Eaton, Keith D ^b   Goodman, Marc T ^d   Tait, Jonathan F ^b   Tewari, Muneesh ^a,b,c   Pritchard, Colin C ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 122; MICRORNA 142 3P; MICRORNA 16; MICRORNA 223; MICRORNA 451; MICRORNA LET 7A; UNCLASSIFIED DRUG;

ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CENTRIFUGATION; CLINICAL ARTICLE; CONTAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FILTRATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PLATELET MICROPARTICLE; PROTEIN EXPRESSION; QUALITY CONTROL; REPRODUCIBILITY; THROMBOCYTE COUNT;

BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOOD SPECIMEN COLLECTION; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; FEMALE; FILTRATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; PLASMA; QUALITY CONTROL;

EID: 84878757129     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064795     Document Type: Article

References (28)

1. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-10518.
2. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, et al. (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-675.
3. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006.
4. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, et al. (2011) MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 8: 467-477.
5. Mostert B, Sieuwerts AM, Martens JW, Sleijfer S, (2011) Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn 11: 259-275.
6. Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, et al. (2010) Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 16: 1745-1755.
7. Zhao X, Qureshi F, Eastman PS, Manning WC, Alexander C, et al. (2012) Pre-analytical effects of blood sampling and handling in quantitative immunoassays for rheumatoid arthritis. J Immunol Methods 378: 72-80.
8. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A, (2011) Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 57: 833-840.
9. Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW, (2011) Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 6: e20769.
10. Kim DJ, Linnstaedt S, Palma J, Park JC, Ntrivalas E, et al. (2012) Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J Mol Diagn 14: 71-80.
11. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, et al. (2012) Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 5: 492-497.
12. Nagalla S, Shaw C, Kong X, Kondkar AA, Edelstein LC, et al. (2011) Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 117: 5189-5197.
13. Osman A, Falker K, (2011) Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes. Platelets 22: 433-441.
14. Simak J, Gelderman MP, (2006) Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 20: 1-26.
15. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, et al. (2007) Hawaii cohort study of serum micronutrient concentrations and clearance of incident oncogenic human papillomavirus infection of the cervix. Cancer Res 67: 5987-5996.
16. Kroh EM, Parkin RK, Mitchell PS, Tewari M, (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50: 298-301.
17. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
18. Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, et al. (2009) Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69: 9490-9497.
19. Aoe K, Hiraki A, Ueoka H, Kiura K, Tabata M, et al. (2004) Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration 71: 170-173.
20. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T, (2008) Prognostic impact of thrombocytosis in resectable non-small cell lung cancer. Interact Cardiovasc Thorac Surg 7: 613-615.
21. Pedersen LM, Milman N, (1996) Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 9: 1826-1830.
22. Hastings ML, Palma J, Duelli DM (2012) Sensitive PCR-based quantitation of cell-free circulating microRNAs. Methods.
23. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, et al. (2010) Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 102: 1174-1179.
24. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, et al. (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251: 499-505.
25. Zeng X, Xiang J, Wu M, Xiong W, Tang H, et al. (2012) Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One 7: e46367.
26. Xu J, Wu C, Che X, Wang L, Yu D, et al. (2011) Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50: 136-142.
27. de Boer HC, van Solingen C, Prins J, Duijs JM, Huisman MV, et al. (2013) Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J.
28. Willeit P, Zampetaki A, Dudek K, Kaudewitz D, King A, et al. (2013) Circulating MicroRNAs as Novel Biomarkers for Platelet Activation. Circ Res 112: 595-600.